FINWIRES · TerminalLIVE
FINWIRES

$REGN

46 stories mentioning REGNUpdated 3d ago

Every FINWIRES story that references REGN, newest first.

What are analysts saying about REGN?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on REGN?

Wire

Regeneron Pharmaceuticals More Likely to Retain Eylea HD Patent, RBC Says

Regeneron Pharmaceuticals' (REGN) patent on Eylea HD is more likely to be retained, with the Patent Trial and Appeal Board, or PTAB, due to issue a final decision on an ongoing patent dispute by March 2027, RBC Capital Markets said in a Thursday note.The patent, which covers Eylea HD's formulation and method of treatment, was issued in 2024 and is set to expire May 10, 2039, according to the note. Alvotech (ALVO) has challenged the patent, with the PTAB to hear arguments on Dec. 4 and issue a decision by March 3, 2027, the brokerage said."Our read and feedback suggests Regeneron is likely in a stronger position, particularly against Alvotech's prior art arguments," RBC said. The patent serves as the company's strongest defense for Eylea HD, blocking potential biosimilars, the investment firm noted.RBC has a sector perform rating on Regeneron Pharmaceuticals, with a $737 price target.Price: $795.00, Change: $-12.65, Percent Change: -1.57%

$ALVO$REGN
Wire

Regeneron Seen Weighing Expanded Sanofi Deal, RBC Says

Regeneron Pharmaceuticals (REGN) may broaden its long-running drug partnership with Sanofi (SNY) to include several new immunology medicines, though any financial benefits would likely take time to show up, RBC Capital Markets said Tuesday in a report.Only Dupixent and Kevzara are currently covered under the collaboration, and both companies have said they're open to renegotiating the agreement, RBC said.The companies could fold additional pipeline drugs into the partnership and potentially update the financial terms, the report said. Regeneron could seek a more even profit split globally, compared with the current structure in which Sanofi funds most development costs upfront and Regeneron reimburses those expenses over time, RBC said.RBC maintained its sector-perform rating on Regeneron stock and its $737 price target.Regeneron shares rose 1.9% in Tuesday trading, and Sanofi gained 0.5%.Price: $814.29, Change: $+15.21, Percent Change: +1.90%

$REGN$SNY
Sectors

Sector Update: Healthcare Stocks Edge Higher Premarket Tuesday

Healthcare stocks were edging higher premarket Tuesday, with the State Street Health Care Select Sector SPDR ETF (XLV) slightly advancing and the iShares Biotechnology ETF (IBB) up 0.2%.Immatics (IMTX) shares were up more than 13% after the company said it has agreed to sell about 12.9 million ordinary shares at $8.69 each, and in lieu of ordinary shares to certain investors, pre-funded warrants to buy up to approximately 4.3 million ordinary shares at $8.689 per pre-funded warrant.Veeva Systems (VEEV) has signed Biogen (BIIB) and Regeneron Pharmaceuticals (REGN) as new users for its Veeva Vault CRM platform, according to statements from Veeva. Shares of Veeva Systems were down 0.1% premarket.Bausch + Lomb (BLCO) stock was up more than 1% after the company said it plans to advance two of its pharmaceutical pipeline assets to new trials based on latest clinical results.

$BIIB$BLCO$IBB$IMTX$REGN$VEEV$XLV
Wire

Regeneron Pharmaceuticals Wins US FDA Approval For Pasatru In Ultra-Rare Musculoskeletal Condition

Regeneron Pharmaceuticals (REGN) has received approval from the US Food and Drug Administration for Pasatru to reduce new heterotopic ossification lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva, or FOP, the drugmaker said Wednesday.FOP is an ultra-rare genetic disorder in which rogue bone formation progressively infiltrates muscles, tendons, ligaments and other connective tissues, causing loss of mobility and potentially making basic activities such as walking, eating and breathing difficult, the company said.The approval was based on phase 3 OPTIMA trial results showing Pasatru reduced new heterotopic ossification lesions by 90% at the 10 mg per kg dose and 94% at the 3 mg per kg dose versus placebo at 56 weeks, the company said.Clinician-assessed flare-ups fell 88% with the 10 mg/kg dose and 15% with the 3 mg per kg dose, the company said.Price: $840.95, Change: $+30.71, Percent Change: +3.79%

$REGN
Wire

Regeneron Pharmaceuticals' Robust Q2 Sales Amid Limited Spend Increases to Help Ramp H2 Margins, RBC Says

Regeneron Pharmaceuticals' (REGN) robust Q2 sales from key products and limited spend increases are expected to help ramp H2 margins, RBC Capital Markets said in a Thursday research report.The company's collaboration with Sanofi (SNY) could become a "more leverageable asset" in advancing immunology and inflammation products if the companies continue to sound more communicative, analysts wrote.A decent uptake of Eylea HD to treat retinal conditions during the quarter is a clear positive for the company, analysts said, adding that they now model Eylea franchise US sales of $3.9 billion in 2026.The brokerage said it reiterated its sector perform rating on the stock and boosted its price target to $737 per share from $696.Price: $736.42, Change: $-1.92, Percent Change: -0.26%

$REGN
Wire

Sector Update: Healthcare Stocks Decline Late Afternoon

Healthcare stocks declined late Thursday afternoon, with the NYSE Healthcare Index shedding 1.5% and the State Street Health Care Select Sector SPDR ETF (XLV) falling 1.7%.The iShares Biotechnology ETF (IBB) was up 0.3%.In corporate news, Xencor (XNCR) shares rose nearly 11% after the company said it has reached a settlement agreement with AstraZeneca (AZN) subsidiary Alexion Pharma International to resolve a commercial dispute over US royalties on Ultomiris. AstraZeneca shares were down 1.2%.Eli Lilly (LLY) expanded its collaboration with Resilience to invest $750 million as part of its effort to boost US production of Lilly's KwikPen injectable device for diabetes and obesity medicines, Resilience said Thursday. Lilly shares were down 4.4%.Johnson & Johnson (JNJ) said it has entered into strategic agreements with Sail Biomedicines to advance the biotech's in vivo CAR-T therapy platform for immune-mediated diseases, including an equity investment and an exclusive option to buy Sail for $2.58 billion. Johnson & Johnson shares fell 3.8%.Bausch Health (BHC) shares surged 26% after it reported higher Q2 results and raised its 2026 revenue outlook.Regeneron Pharmaceuticals (REGN) shares were up 6.3% after it reported higher Q2 results.

$AZN$BHC$JNJ$LLY$REGN$XNCR
Wire

Update: Regeneron Pharmaceuticals Shares Rise After Higher Q2 Results

(Updates with the latest stock movement in the first paragraph and headline.)Regeneron Pharmaceuticals (REGN) shares were up over 5% in Thursday trading after the company reported higher Q2 results.The company reported Q2 adjusted earnings Thursday of $14.29 per diluted share, up from $12.89 a year earlier.Analysts polled by FactSet expected $10.16.Revenue for the quarter ended June 30 was $4.29 billion, up from $3.68 billion a year earlier.Analysts expected $3.82 billion.Price: $728.81, Change: $+33.39, Percent Change: +4.80%

$REGN
Sectors

Sector Update: Healthcare Stocks Decline Premarket Thursday

Healthcare stocks were declining premarket Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 1.4% and the iShares Biotechnology ETF (IBB) 1.6% lower.Johnson & Johnson (JNJ) said it has entered into strategic agreements with Sail Biomedicines to advance the biotech's in vivo CAR-T therapy platform for immune-mediated diseases, including an equity investment and an exclusive option to acquire Sail for $2.58 billion. Shares of Johnson & Johnson were down more than 2% pre-bell.Bristol-Myers Squibb (BMY) stock was down more than 1% even after the company posted higher Q2 non-GAAP earnings and revenue, and raised its 2026 outlook.Regeneron Pharmaceuticals (REGN) shares were up more than 1% after the company reported higher Q2 adjusted earnings and revenue.

$BMY$IBB$JNJ$REGN$XLV
Wire

Cantor Fitzgerald Adjusts Price Target on Regeneron Pharmaceuticals to $750 From $785

Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $825.08, according to analysts polled by FactSet.Price: $671.49, Change: $-0.66, Percent Change: -0.10%

$REGN
Wire

Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says

Biopharma sector's performance in H2 is expected to be driven more by company fundamentals rather than macroeconomic factors, Morgan Stanley said in a note Tuesday.As of July 6, the NYSE Arca Pharmaceutical Index has gained 11% and the Nasdaq Biotechnology Index has added 18%, compared with a 10% gain for the S&P 500 Index, with recent stock performance driven more by changes in valuation multiples than by earnings estimate revisions, the investment bank said.Morgan Stanley said its US Equity Strategy team expects the sector to benefit from broader market leadership. Biotech remains one of the most rate-sensitive sectors, and historically, the sector has delivered nearly 20% annualized returns during falling-rate environments, according to the note.In addition, merger and acquisition activity remains healthy, with several $5 billion to $10 billion deals recently announced, including AbbVie (ABBV) purchasing Apogee (APGE), and Vertex Pharmaceuticals (VRTX) buying Crinetics Pharmaceuticals (CRNX), the investment bank said.Morgan Stanley adjusted its price targets on Biogen (BIIB) to $222 from $224, Amgen (AMGN) to $333 from $340, Gilead Sciences (GILD) to $166 from $168, AbbVie to $279 from $278, Moderna (MRNA) to $39 from $33, BioNTech (BNTX) to $119 from $126, Regeneron Pharmaceuticals (REGN) to $730 from $788, Johnson & Johnson (JNJ) to $284 from $283, and Eli Lilly (LLY) to $1,347 from $1,344.Shares of Biogen, Amgen, Gilead, AbbVie, Moderna, BioNTech, Regeneron, Johnson & Johnson, and Eli Lilly were down 2%, 0.1%, 0.8%, 0.4%, 7%, 1.9%, 1.9%, 0.4%, and 0.5% respectively, in Wednesday trading.Price: $201.67, Change: $-4.03, Percent Change: -1.96%

$ABBV$AMGN$APGE$BIIB$BNTX$CRNX$GILD$JNJ$LLY$MRNA$REGN$VRTX
Wire

MAIA Biotechnology Says Ateganosine Shows 90.5% Disease Control Rate in Phase 2 Expansion Trial

MAIA Biotechnology (MAIA) said Wednesday initial efficacy data from its phase 2 part C expansion trial of ateganosine showed a 90.5% interim disease control rate in patients with advanced non-small cell lung cancer.The company said 21 patients received ateganosine followed by Regeneron Pharmaceuticals' (REGN) Libtayo in 21-day treatment cycles.MAIA added that the initial efficacy results were consistent with the results of the part A and part B studies, despite the part C trial enrolling a more heavily pre-treated patient population.MAIA Biotechnology shares were down 2.4% in Wednesday trading.Price: $1.44, Change: $-0.03, Percent Change: -2.11%

$MAIA$REGN
Wire

Market Chatter: Eli Lilly, Regeneron Among First Companies in FDA PreCheck Pilot Program

Eli Lilly (LLY) and Regeneron Pharmaceuticals (REGN) are among the first seven companies selected by the U.S. Food and Drug Administration for a pilot program aimed at accelerating reviews of new domestic manufacturing facilities, CNBC reported Monday, citing FDA spokesperson Benjamin Nichols.The other participants in the FDA's PreCheck pilot program are Amneal Pharmaceuticals (AMRX), Cellares, Fujifilm Biotechnologies, Kriya Therapeutics and Kyowa Kirin, the report said.The program allows regulators to begin reviewing new manufacturing facilities while they are still under construction, which the agency estimates could save companies up to 14 months, according to the report.Eli Lilly, Regeneron and FDA did not immediately respond to requests for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $1228.24, Change: $+20.12, Percent Change: +1.67%

$AMRX$LLY$REGN
Research

Research Alert: CFRA Lowers Rating On Shares Of Regeneron Pharmaceuticals, Inc To Hold From Buy

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Shares of Regeneron are down more than 10% today after the company announced on Friday evening, after market close, that the Phase 3 study of fianlimab did not achieve a statistically significant primary endpoint in progression-free survival (PFS). The advanced clinical trials were assessing fianlimab in combination with cemiplimab (PD-1 inhibitor) for first-line unresectable or metastatic melanoma, a skin cancer that has spread beyond its original location versus pembrolizumab (PD-1 inhibitor), which is Merck's blockbuster oncology drug, Keytruda. While the company aims to present detailed data at an upcoming medical meeting, the release reflects diminished prospects for what had been anticipated as a highly promising treatment with a blockbuster potential, in our view. We lower our target price to $650 from $846, based on 12.4x our 2027 EPS estimate, a discount to REGN's 10-year historical forward P/E average. We retain our 2026 EPS estimate at $45.59 and our 2027 EPS estimate at $52.62.

$REGN
Asia Markets

US Equity Indexes Off Session Lows as Trump Postpones Iran Attack

US equity indexes closed mixed, albeit off session lows, as President Donald Trump agreed to delay a "large-scale" attack on Iran on Tuesday at the request of leaders from the Middle East negotiating with Tehran.The Nasdaq Composite fell 0.5% to 26,090.73, with the S&P 500 down less than 0.1% to 7,403.05 on Monday. The Dow Jones Industrial Average rose 0.3% to 49,686.12. Technology and industrials led decliners at the close. Energy, financials, and consumer staples were among the top gainers.President Trump will "hold off" on a Tuesday plan to attack Iran, citing a request from Qatar, Saudi Arabia, and the United Arab Emirates as he said negotiations to end the war grow more "serious," CNN reported Monday. "This Deal will include, importantly, NO NUCLEAR WEAPONS FOR IRAN," Trump was cited as saying.Trump also instructed his leadership "to be prepared to go forward with a full, large-scale assault of Iran, on a moment's notice" if a deal isn't reached, according to the president's Truth Social post.Meanwhile, Iran offered an updated peace proposal, which the White House adjudged lacking meaningful improvement over the previous offer, rendering the latest version insufficient to reach a deal to end the war, a senior US official and a source briefed on the issue told Axios.Separately, the US has agreed to release a quarter of Iran's frozen funds - totaling tens of billions of dollars - held in foreign banks, a senior Iranian source told Reuters. Washington has shown more flexibility in allowing Iran to continue some peaceful nuclear activity under the supervision of the International Atomic Energy Agency, the source told the news agency.West Texas Intermediate crude oil futures climbed 1% to $106.48, and Brent crude futures fell 0.4% to $108.83.US Treasury yields slipped after trading mixed earlier in the session. The 10-year was little changed at 4.59%, the highest in about a year. The 30-year rate was steady at 5.13%, the strongest level since 2007.In precious metals, gold futures rose 0.2% to $4,568.8, and silver futures climbed 0.5% to $77.97, clawing back all declines from earlier in the session.In economic news, the National Association of Home Builders' monthly housing market index rose to a reading of 37 in May from 34 in April, compared with expectations for a 34 print in a survey compiled by Bloomberg. The index was above the 34 print reported a year earlier.The New York Federal Reserve's services index improved to minus 5.8 in May from minus 14.0 in April, the highest level since January 2025. The index is the first services sector reading for May and suggests a slower contraction.In company news, NextEra Energy (NEE) and Dominion Energy (D) agreed to merge in an all-stock deal to create the world's largest regulated electric utility. Shares of Dominion jumped 9.4%, the second-biggest gainer on the S&P 500.Regeneron Pharmaceuticals' (REGN) miss on the fianlimab trial may lead some investors to question the company's broader strategy and execution, RBC Capital Markets said. Regeneron's shares sank 9.8%, the steepest decline on the S&P 500 and the Nasdaq.

Dow JonesNasdaq CompositeS&P 500$D$NEE$REGN
International

US Equity Markets Mixed as Investors Weigh Reports of Iran's Updated Peace Proposal

US equity indexes were mixed on Monday as investors weighed reports of an updated peace proposal from Iran.* Iran has offered an updated proposal, which the White House sees as lacking meaningful improvement over the previous offer, rendering the latest version insufficient to reach a deal to end the war, a senior US official and a source briefed on the issue told Axios.* The National Association of Home Builders' monthly housing market index rose to a reading of 37 in May from 34 in April, compared with expectations for a 34 print in a survey compiled by Bloomberg.* The New York Federal Reserve's services index improved to minus 5.8 in May from minus 14.0 in April, the highest level since January 2025.* June West Texas Intermediate crude oil rose $0.73 to settle at $106.15 per barrel, while July Brent crude, the global benchmark, was last seen down $0.02 at $109.18.* NextEra Energy (NEE) and Dominion Energy (D) agreed to merge in an all-stock deal to create the world's largest regulated electric utility. Shares of Dominion were up about 9.3%, the biggest gainer on the S&P 500.* Regeneron Pharmaceuticals' (REGN) miss on the fianlimab trial may lead some investors to question the company's broader strategy and execution, RBC Capital Markets said in a note. Regeneron's shares fell nearly 10%, the steepest decline on the S&P 500 and the Nasdaq.

Dow JonesNasdaq CompositeS&P 500$D$NEE$REGN
Wire

Top Midday Decliners

Regeneron Pharmaceuticals (REGN) said two dose levels of fianlimab in combination with cemiplimab, evaluated as a first-line treatment in unresectable locally advanced or metastatic melanoma, failed to meet a primary endpoint in its phase 3 trial.The company's stock dropped 10% as intraday volume topped 2.17 million shares versus the daily average of about 685,000.Seagate Technology's (STX) shares slumped 9.7% after CEO Dave Mosley said building new factories to meet demand would "take too long."Intraday volume topped 3.05 million shares versus the daily average of about 3.97 million.Air Global's (AIIR) shares fell 23% in their Nasdaq debut with volume of about 29,500.Price: $628.30, Change: $-69.95, Percent Change: -10.02%

$AIIR$REGN$STX
Asia Markets

US Equity Indexes Mixed, Crude Oil Rises as Iran Reportedly Sends Revised Peace Proposal

US equity indexes traded mixed as crude oil futures rose and government bond yields remained elevated after midday Monday amid reports of an updated peace proposal from Iran to end the war.The Nasdaq Composite fell 0.7% to 26,047.1, with the S&P 500 down 0.3% to 7,389.2. The Dow Jones Industrial Average rose 0.1% to 49,595.5.Technology and industrials led decliners intraday. Energy, financials, and communication services were among the top gainers.Iran has offered an updated proposal, which the White House sees as lacking meaningful improvement over the previous offer, rendering the latest version insufficient to reach a deal to end the war, a senior US official and a source briefed on the issue told Axios.However, a senior Iranian source told Reuters that the US had agreed to release a quarter of Iran's frozen funds - totaling tens of billions of dollars - held in foreign banks. The Iranian source also told the news agency that Washington has shown more flexibility in allowing Iran to continue some peaceful nuclear activity under the supervision of the International Atomic Energy Agency.Meanwhile, President Donald Trump is expected to meet top national security advisers on Tuesday to discuss options for resuming military action, Axios said in a separate news report. "The Clock is Ticking" for Iran, Trump said in a post on Truth Social at the weekend, adding that "they better get moving, FAST, or there won't be anything left of them. TIME IS OF THE ESSENCE!"West Texas Intermediate crude oil futures climbed 0.9% to $106.24, and Brent crude futures advanced 0.9% to $110.28.US Treasury yields traded mixed, but elevated. The 10-year was little changed at 4.6%, the highest since January 2025. The 30-year rate was steady at 5.13%, the strongest level since 2007.In precious metals, gold futures slipped 0.1% to $4,558.1, and silver futures were steady at $77.59.In economic news, the National Association of Home Builders' monthly housing market index rose to a reading of 37 in May from 34 in April, compared with expectations for a 34 print in a survey compiled by Bloomberg. The index was above the 34 print reported a year earlier."Recent increases for long-term interest rates will continue to hold back home buyer demand," said NAHB Chief Economist Robert Dietz. "Although some regional markets, including parts of the Midwest, are showing relative strength, the housing market continues to face significant affordability challenges."The New York Federal Reserve's services index improved to minus 5.8 in May from minus 14.0 in April, the highest level since January 2025. The index is the first services sector reading for May and suggests a slower contraction.In company news, NextEra Energy (NEE) and Dominion Energy (D) agreed to merge in an all-stock deal to create the world's largest regulated electric utility. Shares of Dominion jumped 8.8%, the second-biggest gainer on the S&P 500.Regeneron Pharmaceuticals' (REGN) miss on the fianlimab trial may lead some investors to question the company's broader strategy and execution, RBC Capital Markets said. Regeneron's shares sank 9.7%, the steepest decline on the S&P 500 and the Nasdaq.

Dow JonesNasdaq CompositeS&P 500$D$NEE$REGN
Research

Research Alert: CFRA Lowers Rating On Shares Of Regeneron Pharmaceuticals, Inc To Hold From Buy

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Shares of Regeneron are down more than 10% today after the company announced on Friday evening, after market close, that the Phase 3 study of fianlimab did not achieve a statistically significant primary endpoint in progression-free survival (PFS). The advanced clinical trials were assessing fianlimab in combination with cemiplimab (PD-1 inhibitor) for first-line unresectable or metastatic melanoma, a skin cancer that has spread beyond its original location versus pembrolizumab (PD-1 inhibitor), which is Merck's blockbuster oncology drug, Keytruda. While the company aims to present detailed data at an upcoming medical meeting, the release reflects diminished prospects for what had been anticipated as a highly promising treatment with a blockbuster potential, in our view. We lower our target price to $650 from $846, based on 12.4x our 2027 EPS estimate, a discount to REGN's 10-year historical forward P/E average. We retain our 2026 EPS estimate at $45.59 and our 2027 EPS estimate at $52.62.

$REGN
Wire

Canaccord Genuity Cuts Regeneron Pharmaceuticals Price Target to $875 From $1,057, Maintains Buy Rating

Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $839.77, according to analysts polled by FactSet.Price: $630.74, Change: $-67.51, Percent Change: -9.67%

$REGN
Wire

Regeneron Pharmaceuticals Trial Miss May Raise Broader Strategy Questions, RBC Says

Regeneron Pharmaceuticals' (REGN) fianlimab trial miss might lead some investors to question the company's broader strategy and execution, RBC Capital Markets said.The company reported late Friday that two dose levels of fianlimab in combination with cemiplimab, evaluated as a first-line treatment in unresectable locally advanced or metastatic melanoma, failed to meet a primary endpoint in its phase 3 trial.RBC said the miss was disappointing as they had estimated peak worldwide probability-adjusted sales of about $1.6 billion to $1.8 billion for the drug, making it a meaningful setback for the company's pipeline.The investment firm said it does not see the miss as critical given several ongoing strengths, including continued strong growth from Dupixent, improving momentum for Eylea HD, expanded Dupixent lifecycle initiatives, and the expected increase in Sanofi (SNY) royalty contributions.The brokerage said this failure adds to a series of recent missteps, including the itepekimab setback, a less competitive launch label for Eylea HD, and manufacturing issues. Together, these events may lead some skeptics to question the company's overall direction."In short, near-miss is a tough break, and still there are lots of pipeline and other drivers, but disappointment in light of high expectations going in could raise bigger-picture questions," according to the note Sunday.RBC lowered its price target on Regeneron Pharmaceuticals to $707 from $762 while keeping its sector perform rating.Shares of Regeneron were down more than 10% in Monday trading.Price: $626.50, Change: $-71.76, Percent Change: -10.28%

$REGN

Showing 1-20 of 46

Track with the FINWIRES app suite

FolioX
FolioX
Track REGN in your portfolio
WheelAI
WheelAI
Analyze REGN options with the wheel strategy
StockInsider
StockInsider
See market sentiment on REGN